Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]
Spruce Biosciences, Inc. (SPRB)
Company Research
Source: Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., December 15, 2025 BUSINESS WIRE )--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors. "Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB)," said Michael Grey, Executive Chairman of Spruce Biosciences. "Her experience in successfully launching multiple drugs and her deep understanding of the rare disease commercial landscape will help support our transition into a commercial-stage organization focused on delivering potentially the first disease-modifying therapy for children with MPS IIIB." Ms. Walbert has more than 20 years of experience leading teams across commercial functions, including marketing a
Show less
Read more
Impact Snapshot
Event Time:
SPRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRB alerts
High impacting Spruce Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
SPRB
News
- Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of DirectorsBusiness Wire
- Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SPRB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.MarketBeat
- Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SPRB
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- SPRB's page on the SEC website